RETRACTED ARTICLE: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience

Ebada Mohamed Said, Badawy A. Abdulaziz, Mohamed El Kassas, Ibrahim Hussein El Attar, Mohammed Emadeldeen, Sherief M. Abd-Elsalam

Open source

DOI: 10.1007/s00705-020-04639-x
Published: 2020-04-30
Container: Archives of Virology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

serious concern Score 29/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00705-020-04639-x,
  title = {RETRACTED ARTICLE: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience},
  author = {Ebada Mohamed Said and Badawy A. Abdulaziz and Mohamed El Kassas and Ibrahim Hussein El Attar and Mohammed Emadeldeen and Sherief M. Abd-Elsalam},
  year = {2020},
  journal = {Archives of Virology},
  doi = {10.1007/s00705-020-04639-x},
  url = {https://doi.org/10.1007/s00705-020-04639-x}
}

RIS

TY  - JOUR
TI  - RETRACTED ARTICLE: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience
AU  - Ebada Mohamed Said
AU  - Badawy A. Abdulaziz
AU  - Mohamed El Kassas
AU  - Ibrahim Hussein El Attar
AU  - Mohammed Emadeldeen
AU  - Sherief M. Abd-Elsalam
PY  - 2020
JO  - Archives of Virology
DO  - 10.1007/s00705-020-04639-x
UR  - https://doi.org/10.1007/s00705-020-04639-x
ER  -

APA

Said, E. M., Abdulaziz, B. A., Kassas, M. E., Attar, I. H. E., Emadeldeen, M., & Abd-Elsalam, S. M. (2020). RETRACTED ARTICLE: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience. Archives of Virology. https://doi.org/10.1007/s00705-020-04639-x

Source records

crossref · retrieved 2026-09-25T10:30:48.793Z